Trial Outcomes & Findings for Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia (NCT NCT04827147)

NCT ID: NCT04827147

Last Updated: 2026-08-19

Results Overview

Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

64 participants

Primary outcome timeframe

Immediately after each 4-week intervention

Results posted on

2026-08-19

Participant Flow

Participants were recruited between April 2023 and November 2024 at seven vision rehabilitation clinics in the United States, including three university clinics, three academic medical centers and one private practice.

64 participants were screened. 26 did not meet eligibility criteria and were excluded All 38 participants who met eligibility criteria were allocated to receive either MPP first (n=19) or FPP first (n=19). One allocation was mistakenly swopped; therefore 18 participants started in the MPP first group and 20 in the FPP first group.

Participant milestones

Participant milestones
Measure
MPP First, FPP Second
Participants in this arm received the MPP in the first period of the crossover and the FPP in the second period.
FPP First, MPP Second
Participants in this arm received the FPP in the first period of the crossover and the MPP in the second period.
First crossover period
STARTED
18
20
First crossover period
COMPLETED
17
17
First crossover period
NOT COMPLETED
1
3
Second crossover period
STARTED
17
17
Second crossover period
COMPLETED
16
16
Second crossover period
NOT COMPLETED
1
1

Reasons for withdrawal

Reasons for withdrawal
Measure
MPP First, FPP Second
Participants in this arm received the MPP in the first period of the crossover and the FPP in the second period.
FPP First, MPP Second
Participants in this arm received the FPP in the first period of the crossover and the MPP in the second period.
First crossover period
Withdrawal by Subject
1
3
Second crossover period
Withdrawal by Subject
1
1

Baseline Characteristics

Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
MPP First, FPP Second
n=18 Participants
Participants in this arm received the MPP in the first period of the crossover and the FPP in the second period.
FPP First, MPP Second
n=20 Participants
Participants in this arm received the FPP in the first period of the crossover and the MPP in the second period.
Total
n=38 Participants
Total of all reporting groups
Age, Continuous
57 Years
n=298 Participants
57 Years
n=102 Participants
57 Years
n=400 Participants
Sex: Female, Male
Female
4 Participants
n=298 Participants
7 Participants
n=102 Participants
11 Participants
n=400 Participants
Sex: Female, Male
Male
14 Participants
n=298 Participants
13 Participants
n=102 Participants
27 Participants
n=400 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=298 Participants
0 Participants
n=102 Participants
0 Participants
n=400 Participants
Race (NIH/OMB)
Asian
0 Participants
n=298 Participants
0 Participants
n=102 Participants
0 Participants
n=400 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=298 Participants
0 Participants
n=102 Participants
0 Participants
n=400 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=298 Participants
2 Participants
n=102 Participants
6 Participants
n=400 Participants
Race (NIH/OMB)
White
14 Participants
n=298 Participants
15 Participants
n=102 Participants
29 Participants
n=400 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=298 Participants
0 Participants
n=102 Participants
0 Participants
n=400 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=298 Participants
3 Participants
n=102 Participants
3 Participants
n=400 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=298 Participants
3 Participants
n=102 Participants
5 Participants
n=400 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
16 Participants
n=298 Participants
17 Participants
n=102 Participants
33 Participants
n=400 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=298 Participants
0 Participants
n=102 Participants
0 Participants
n=400 Participants

PRIMARY outcome

Timeframe: Immediately after each 4-week intervention

Population: An intention to treat analysis was used including all 38 participants who started the first period of the crossover. Participants who withdrew before the end of the second period of the crossover were entered into the analysis as no improvement with FPPs and no improvement with MPPs.

Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.

Outcome measures

Outcome measures
Measure
All Participants Who Were Allocated
n=38 Participants
Includes all participants in the two treatment allocation groups (i.e. data are pooled across the two groups)
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees
Improved with MPPs
12 Participants
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 40 Degrees
Improved with FPPs
10 Participants

SECONDARY outcome

Timeframe: Immediately after each 4-week intervention

Population: An intention to treat analysis was used including all 38 participants who started the first period of the crossover. Participants who withdrew before the end of the second period of the crossover were entered into the analysis as no improvement with FPPs and no improvement with MPPs.

Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 20 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.

Outcome measures

Outcome measures
Measure
All Participants Who Were Allocated
n=38 Participants
Includes all participants in the two treatment allocation groups (i.e. data are pooled across the two groups)
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 20 Degrees
Improved with MPPs
14 Participants
Improvement in Blind-side Detection Rate for Hazards Approaching at a Bearing Angle of 20 Degrees
Improved with FPPs
16 Participants

SECONDARY outcome

Timeframe: Immediately after the second 4-week intervention

Number of participants selecting each device as a percentage of the total number of participants enrolled

Outcome measures

Outcome measures
Measure
All Participants Who Were Allocated
n=32 Participants
Includes all participants in the two treatment allocation groups (i.e. data are pooled across the two groups)
Device Preference
Preferred MPPs
13 Participants
Device Preference
Preferred FPPs
19 Participants

Adverse Events

MPP All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

FPP All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alex Bowers

Schepens Eye Research Institute of Mass Eye and Ear

Phone: 617 912 2512

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place